nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—UGT2B7—Epirubicin—peripheral nervous system neoplasm	0.236	0.644	CbGbCtD
Tapentadol—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.0773	0.211	CbGbCtD
Tapentadol—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.0331	0.0902	CbGbCtD
Tapentadol—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.0203	0.0553	CbGbCtD
Tapentadol—HTR3A—vagus nerve—peripheral nervous system neoplasm	0.015	0.181	CbGeAlD
Tapentadol—HTR3A—cranial nerve—peripheral nervous system neoplasm	0.0114	0.138	CbGeAlD
Tapentadol—Edrophonium—BCHE—peripheral nervous system neoplasm	0.00867	0.518	CrCbGaD
Tapentadol—Rivastigmine—BCHE—peripheral nervous system neoplasm	0.00806	0.482	CrCbGaD
Tapentadol—OPRD1—ganglion—peripheral nervous system neoplasm	0.00779	0.0937	CbGeAlD
Tapentadol—HTR3A—nerve—peripheral nervous system neoplasm	0.00587	0.0706	CbGeAlD
Tapentadol—HTR3A—ganglion—peripheral nervous system neoplasm	0.00579	0.0697	CbGeAlD
Tapentadol—OPRM1—nerve—peripheral nervous system neoplasm	0.00538	0.0647	CbGeAlD
Tapentadol—OPRM1—ganglion—peripheral nervous system neoplasm	0.00531	0.0639	CbGeAlD
Tapentadol—SLC6A4—ganglion—peripheral nervous system neoplasm	0.00442	0.0531	CbGeAlD
Tapentadol—SLC6A2—nerve—peripheral nervous system neoplasm	0.00394	0.0474	CbGeAlD
Tapentadol—SLC6A2—ganglion—peripheral nervous system neoplasm	0.00389	0.0468	CbGeAlD
Tapentadol—HTR3A—trigeminal ganglion—peripheral nervous system neoplasm	0.00285	0.0342	CbGeAlD
Tapentadol—HTR3A—brainstem—peripheral nervous system neoplasm	0.00252	0.0303	CbGeAlD
Tapentadol—OPRM1—brainstem—peripheral nervous system neoplasm	0.00231	0.0278	CbGeAlD
Tapentadol—SLC6A4—brainstem—peripheral nervous system neoplasm	0.00192	0.0231	CbGeAlD
Tapentadol—SLC6A2—brainstem—peripheral nervous system neoplasm	0.00169	0.0203	CbGeAlD
Tapentadol—OPRK1—cerebellum—peripheral nervous system neoplasm	0.0016	0.0193	CbGeAlD
Tapentadol—CYP2D6—brainstem—peripheral nervous system neoplasm	0.000926	0.0111	CbGeAlD
Tapentadol—UGT2B7—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	0.000861	0.0664	CbGpPWpGaD
Tapentadol—SLC6A4—Synaptic Vesicle Pathway—SYP—peripheral nervous system neoplasm	0.000775	0.0598	CbGpPWpGaD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—PHOX2B—peripheral nervous system neoplasm	0.000597	0.0461	CbGpPWpGaD
Tapentadol—UGT1A9—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.000593	0.0458	CbGpPWpGaD
Tapentadol—Paraesthesia—Vincristine—peripheral nervous system neoplasm	0.000593	0.00114	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.000592	0.00114	CcSEcCtD
Tapentadol—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.000591	0.00114	CcSEcCtD
Tapentadol—Vertigo—Etoposide—peripheral nervous system neoplasm	0.000589	0.00113	CcSEcCtD
Tapentadol—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.000586	0.00113	CcSEcCtD
Tapentadol—Oedema—Cisplatin—peripheral nervous system neoplasm	0.000584	0.00112	CcSEcCtD
Tapentadol—Anaphylactic shock—Cisplatin—peripheral nervous system neoplasm	0.000584	0.00112	CcSEcCtD
Tapentadol—Infection—Cisplatin—peripheral nervous system neoplasm	0.00058	0.00112	CcSEcCtD
Tapentadol—Vomiting—Topotecan—peripheral nervous system neoplasm	0.00058	0.00111	CcSEcCtD
Tapentadol—Loss of consciousness—Etoposide—peripheral nervous system neoplasm	0.000576	0.00111	CcSEcCtD
Tapentadol—Lethargy—Doxorubicin—peripheral nervous system neoplasm	0.000576	0.00111	CcSEcCtD
Tapentadol—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000575	0.00111	CcSEcCtD
Tapentadol—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000575	0.00111	CcSEcCtD
Tapentadol—Rash—Topotecan—peripheral nervous system neoplasm	0.000575	0.00111	CcSEcCtD
Tapentadol—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000574	0.0011	CcSEcCtD
Tapentadol—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.000574	0.0011	CcSEcCtD
Tapentadol—Ataxia—Epirubicin—peripheral nervous system neoplasm	0.000574	0.0011	CcSEcCtD
Tapentadol—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000573	0.0011	CcSEcCtD
Tapentadol—Cough—Etoposide—peripheral nervous system neoplasm	0.000572	0.0011	CcSEcCtD
Tapentadol—Headache—Topotecan—peripheral nervous system neoplasm	0.000571	0.0011	CcSEcCtD
Tapentadol—Rash—Tretinoin—peripheral nervous system neoplasm	0.00057	0.0011	CcSEcCtD
Tapentadol—Rash—Isotretinoin—peripheral nervous system neoplasm	0.00057	0.0011	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.00057	0.0011	CcSEcCtD
Tapentadol—Tachycardia—Cisplatin—peripheral nervous system neoplasm	0.00057	0.0011	CcSEcCtD
Tapentadol—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.00057	0.0011	CcSEcCtD
Tapentadol—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.00057	0.0011	CcSEcCtD
Tapentadol—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000569	0.0011	CcSEcCtD
Tapentadol—Convulsion—Etoposide—peripheral nervous system neoplasm	0.000568	0.00109	CcSEcCtD
Tapentadol—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000568	0.00109	CcSEcCtD
Tapentadol—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000567	0.00109	CcSEcCtD
Tapentadol—Headache—Tretinoin—peripheral nervous system neoplasm	0.000567	0.00109	CcSEcCtD
Tapentadol—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000567	0.00109	CcSEcCtD
Tapentadol—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.000565	0.00109	CcSEcCtD
Tapentadol—Constipation—Vincristine—peripheral nervous system neoplasm	0.000565	0.00109	CcSEcCtD
Tapentadol—Osteoarthritis—Doxorubicin—peripheral nervous system neoplasm	0.000565	0.00109	CcSEcCtD
Tapentadol—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.000565	0.00109	CcSEcCtD
Tapentadol—Rash—Melphalan—peripheral nervous system neoplasm	0.000563	0.00108	CcSEcCtD
Tapentadol—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000562	0.00108	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000554	0.00107	CcSEcCtD
Tapentadol—Breast disorder—Epirubicin—peripheral nervous system neoplasm	0.000551	0.00106	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000549	0.00106	CcSEcCtD
Tapentadol—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.000546	0.00105	CcSEcCtD
Tapentadol—Nasopharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000546	0.00105	CcSEcCtD
Tapentadol—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000545	0.00105	CcSEcCtD
Tapentadol—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000545	0.00105	CcSEcCtD
Tapentadol—Nausea—Topotecan—peripheral nervous system neoplasm	0.000542	0.00104	CcSEcCtD
Tapentadol—Confusional state—Etoposide—peripheral nervous system neoplasm	0.000539	0.00104	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000538	0.00104	CcSEcCtD
Tapentadol—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000537	0.00103	CcSEcCtD
Tapentadol—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000537	0.00103	CcSEcCtD
Tapentadol—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000535	0.00103	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000532	0.00102	CcSEcCtD
Tapentadol—Infection—Etoposide—peripheral nervous system neoplasm	0.000532	0.00102	CcSEcCtD
Tapentadol—Ataxia—Doxorubicin—peripheral nervous system neoplasm	0.000531	0.00102	CcSEcCtD
Tapentadol—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.00053	0.00102	CcSEcCtD
Tapentadol—Nausea—Melphalan—peripheral nervous system neoplasm	0.00053	0.00102	CcSEcCtD
Tapentadol—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000524	0.00101	CcSEcCtD
Tapentadol—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000522	0.001	CcSEcCtD
Tapentadol—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000521	0.001	CcSEcCtD
Tapentadol—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.00052	0.001	CcSEcCtD
Tapentadol—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000517	0.000995	CcSEcCtD
Tapentadol—Breast disorder—Doxorubicin—peripheral nervous system neoplasm	0.00051	0.000981	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000508	0.000978	CcSEcCtD
Tapentadol—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000508	0.000976	CcSEcCtD
Tapentadol—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000506	0.000973	CcSEcCtD
Tapentadol—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000505	0.000971	CcSEcCtD
Tapentadol—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000505	0.000971	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000504	0.00097	CcSEcCtD
Tapentadol—Hypotension—Etoposide—peripheral nervous system neoplasm	0.0005	0.000962	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000498	0.000958	CcSEcCtD
Tapentadol—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000492	0.000946	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.00049	0.000943	CcSEcCtD
Tapentadol—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	0.000487	0.000937	CcSEcCtD
Tapentadol—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000487	0.000936	CcSEcCtD
Tapentadol—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000485	0.000933	CcSEcCtD
Tapentadol—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000481	0.000926	CcSEcCtD
Tapentadol—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.00048	0.000924	CcSEcCtD
Tapentadol—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000477	0.000918	CcSEcCtD
Tapentadol—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000477	0.000917	CcSEcCtD
Tapentadol—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000476	0.000915	CcSEcCtD
Tapentadol—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000474	0.000911	CcSEcCtD
Tapentadol—Infestation—Epirubicin—peripheral nervous system neoplasm	0.00047	0.000904	CcSEcCtD
Tapentadol—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.00047	0.000904	CcSEcCtD
Tapentadol—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.00047	0.000904	CcSEcCtD
Tapentadol—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000469	0.000902	CcSEcCtD
Tapentadol—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000466	0.000897	CcSEcCtD
Tapentadol—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000465	0.000895	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000462	0.000888	CcSEcCtD
Tapentadol—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000461	0.000887	CcSEcCtD
Tapentadol—Constipation—Etoposide—peripheral nervous system neoplasm	0.000458	0.00088	CcSEcCtD
Tapentadol—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000457	0.000879	CcSEcCtD
Tapentadol—CYP2D6—cerebellum—peripheral nervous system neoplasm	0.000456	0.00549	CbGeAlD
Tapentadol—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000454	0.000872	CcSEcCtD
Tapentadol—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000453	0.000872	CcSEcCtD
Tapentadol—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000452	0.000869	CcSEcCtD
Tapentadol—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	0.000451	0.000867	CcSEcCtD
Tapentadol—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.000441	0.000849	CcSEcCtD
Tapentadol—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000441	0.000848	CcSEcCtD
Tapentadol—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000439	0.000845	CcSEcCtD
Tapentadol—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000437	0.00084	CcSEcCtD
Tapentadol—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000436	0.000838	CcSEcCtD
Tapentadol—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000435	0.000837	CcSEcCtD
Tapentadol—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000435	0.000837	CcSEcCtD
Tapentadol—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000432	0.000831	CcSEcCtD
Tapentadol—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000432	0.00083	CcSEcCtD
Tapentadol—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.00043	0.000828	CcSEcCtD
Tapentadol—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.00043	0.000827	CcSEcCtD
Tapentadol—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000429	0.000826	CcSEcCtD
Tapentadol—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000425	0.000818	CcSEcCtD
Tapentadol—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000423	0.000813	CcSEcCtD
Tapentadol—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.00042	0.000808	CcSEcCtD
Tapentadol—Vomiting—Vincristine—peripheral nervous system neoplasm	0.00042	0.000808	CcSEcCtD
Tapentadol—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000419	0.000806	CcSEcCtD
Tapentadol—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000417	0.000802	CcSEcCtD
Tapentadol—Rash—Vincristine—peripheral nervous system neoplasm	0.000416	0.000801	CcSEcCtD
Tapentadol—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000416	0.0008	CcSEcCtD
Tapentadol—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000415	0.000798	CcSEcCtD
Tapentadol—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000414	0.000796	CcSEcCtD
Tapentadol—Headache—Vincristine—peripheral nervous system neoplasm	0.000414	0.000796	CcSEcCtD
Tapentadol—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000407	0.000783	CcSEcCtD
Tapentadol—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.000407	0.000782	CcSEcCtD
Tapentadol—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.0004	0.000769	CcSEcCtD
Tapentadol—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.000398	0.000765	CcSEcCtD
Tapentadol—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.000395	0.000759	CcSEcCtD
Tapentadol—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000394	0.000758	CcSEcCtD
Tapentadol—Nausea—Vincristine—peripheral nervous system neoplasm	0.000392	0.000755	CcSEcCtD
Tapentadol—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000392	0.000754	CcSEcCtD
Tapentadol—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000389	0.000748	CcSEcCtD
Tapentadol—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000386	0.000742	CcSEcCtD
Tapentadol—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000384	0.000738	CcSEcCtD
Tapentadol—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.000384	0.000738	CcSEcCtD
Tapentadol—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000383	0.000737	CcSEcCtD
Tapentadol—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000383	0.000736	CcSEcCtD
Tapentadol—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000381	0.000733	CcSEcCtD
Tapentadol—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.00038	0.000732	CcSEcCtD
Tapentadol—Chills—Epirubicin—peripheral nervous system neoplasm	0.000379	0.000729	CcSEcCtD
Tapentadol—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000379	0.000728	CcSEcCtD
Tapentadol—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	0.000376	0.000724	CcSEcCtD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—PHOX2B—peripheral nervous system neoplasm	0.000372	0.0288	CbGpPWpGaD
Tapentadol—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000371	0.000714	CcSEcCtD
Tapentadol—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.00037	0.000711	CcSEcCtD
Tapentadol—Rash—Cisplatin—peripheral nervous system neoplasm	0.000368	0.000708	CcSEcCtD
Tapentadol—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000368	0.000708	CcSEcCtD
Tapentadol—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000367	0.000707	CcSEcCtD
Tapentadol—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000366	0.000704	CcSEcCtD
Tapentadol—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.000365	0.000702	CcSEcCtD
Tapentadol—OPRK1—Mecp2 and Associated Rett Syndrome—NF1—peripheral nervous system neoplasm	0.000364	0.0281	CbGpPWpGaD
Tapentadol—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000363	0.000697	CcSEcCtD
Tapentadol—Tension—Epirubicin—peripheral nervous system neoplasm	0.000361	0.000694	CcSEcCtD
Tapentadol—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.000357	0.000687	CcSEcCtD
Tapentadol—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000354	0.000682	CcSEcCtD
Tapentadol—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000354	0.000681	CcSEcCtD
Tapentadol—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000353	0.000679	CcSEcCtD
Tapentadol—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000352	0.000677	CcSEcCtD
Tapentadol—Chills—Doxorubicin—peripheral nervous system neoplasm	0.00035	0.000674	CcSEcCtD
Tapentadol—SLC6A4—Monoamine Transport—TH—peripheral nervous system neoplasm	0.000349	0.0269	CbGpPWpGaD
Tapentadol—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000347	0.000667	CcSEcCtD
Tapentadol—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000346	0.000666	CcSEcCtD
Tapentadol—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.000342	0.000658	CcSEcCtD
Tapentadol—Vomiting—Etoposide—peripheral nervous system neoplasm	0.00034	0.000654	CcSEcCtD
Tapentadol—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.00034	0.000654	CcSEcCtD
Tapentadol—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000338	0.00065	CcSEcCtD
Tapentadol—Rash—Etoposide—peripheral nervous system neoplasm	0.000337	0.000649	CcSEcCtD
Tapentadol—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000337	0.000648	CcSEcCtD
Tapentadol—Headache—Etoposide—peripheral nervous system neoplasm	0.000335	0.000645	CcSEcCtD
Tapentadol—Tension—Doxorubicin—peripheral nervous system neoplasm	0.000334	0.000642	CcSEcCtD
Tapentadol—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.00033	0.000635	CcSEcCtD
Tapentadol—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.00033	0.000635	CcSEcCtD
Tapentadol—Syncope—Epirubicin—peripheral nervous system neoplasm	0.00033	0.000634	CcSEcCtD
Tapentadol—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000325	0.000625	CcSEcCtD
Tapentadol—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000323	0.000621	CcSEcCtD
Tapentadol—Cough—Epirubicin—peripheral nervous system neoplasm	0.000321	0.000617	CcSEcCtD
Tapentadol—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.00032	0.000616	CcSEcCtD
Tapentadol—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.000318	0.000612	CcSEcCtD
Tapentadol—Nausea—Etoposide—peripheral nervous system neoplasm	0.000318	0.000611	CcSEcCtD
Tapentadol—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.000313	0.000602	CcSEcCtD
Tapentadol—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.000312	0.000601	CcSEcCtD
Tapentadol—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000312	0.0006	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000311	0.000598	CcSEcCtD
Tapentadol—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000306	0.000589	CcSEcCtD
Tapentadol—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.000305	0.000588	CcSEcCtD
Tapentadol—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000305	0.000587	CcSEcCtD
Tapentadol—Confusional state—Epirubicin—peripheral nervous system neoplasm	0.000302	0.000582	CcSEcCtD
Tapentadol—CYP2D6—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	0.000302	0.0233	CbGpPWpGaD
Tapentadol—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.0003	0.000578	CcSEcCtD
Tapentadol—SLC6A2—Monoamine Transport—TH—peripheral nervous system neoplasm	0.0003	0.0232	CbGpPWpGaD
Tapentadol—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.0003	0.000577	CcSEcCtD
Tapentadol—Oedema—Epirubicin—peripheral nervous system neoplasm	0.0003	0.000577	CcSEcCtD
Tapentadol—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000299	0.000575	CcSEcCtD
Tapentadol—Infection—Epirubicin—peripheral nervous system neoplasm	0.000298	0.000573	CcSEcCtD
Tapentadol—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000297	0.000571	CcSEcCtD
Tapentadol—Shock—Epirubicin—peripheral nervous system neoplasm	0.000295	0.000568	CcSEcCtD
Tapentadol—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.000295	0.000567	CcSEcCtD
Tapentadol—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000294	0.000566	CcSEcCtD
Tapentadol—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000293	0.000563	CcSEcCtD
Tapentadol—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000291	0.00056	CcSEcCtD
Tapentadol—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.00029	0.000558	CcSEcCtD
Tapentadol—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000289	0.000557	CcSEcCtD
Tapentadol—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000288	0.000555	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000287	0.000553	CcSEcCtD
Tapentadol—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000283	0.000545	CcSEcCtD
Tapentadol—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.00028	0.000539	CcSEcCtD
Tapentadol—Confusional state—Doxorubicin—peripheral nervous system neoplasm	0.00028	0.000538	CcSEcCtD
Tapentadol—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.000278	0.000534	CcSEcCtD
Tapentadol—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.000278	0.000534	CcSEcCtD
Tapentadol—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000276	0.00053	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000273	0.000526	CcSEcCtD
Tapentadol—Shock—Doxorubicin—peripheral nervous system neoplasm	0.000273	0.000525	CcSEcCtD
Tapentadol—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000272	0.000523	CcSEcCtD
Tapentadol—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000271	0.000522	CcSEcCtD
Tapentadol—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000271	0.000521	CcSEcCtD
Tapentadol—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.00027	0.000518	CcSEcCtD
Tapentadol—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.000269	0.000518	CcSEcCtD
Tapentadol—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000268	0.000516	CcSEcCtD
Tapentadol—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000267	0.000514	CcSEcCtD
Tapentadol—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000267	0.000513	CcSEcCtD
Tapentadol—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000264	0.000508	CcSEcCtD
Tapentadol—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000261	0.000501	CcSEcCtD
Tapentadol—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000259	0.000499	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000259	0.000498	CcSEcCtD
Tapentadol—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000259	0.000497	CcSEcCtD
Tapentadol—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000256	0.000493	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000253	0.000486	CcSEcCtD
Tapentadol—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000251	0.000483	CcSEcCtD
Tapentadol—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000249	0.000479	CcSEcCtD
Tapentadol—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000247	0.000476	CcSEcCtD
Tapentadol—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000247	0.000475	CcSEcCtD
Tapentadol—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000247	0.000475	CcSEcCtD
Tapentadol—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.000244	0.00047	CcSEcCtD
Tapentadol—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000241	0.000464	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.00024	0.000461	CcSEcCtD
Tapentadol—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000239	0.00046	CcSEcCtD
Tapentadol—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000238	0.000458	CcSEcCtD
Tapentadol—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000237	0.000456	CcSEcCtD
Tapentadol—UGT1A9—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000231	0.0178	CbGpPWpGaD
Tapentadol—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000229	0.00044	CcSEcCtD
Tapentadol—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000221	0.000425	CcSEcCtD
Tapentadol—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.00022	0.000424	CcSEcCtD
Tapentadol—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000215	0.000414	CcSEcCtD
Tapentadol—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000212	0.000408	CcSEcCtD
Tapentadol—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—HSD17B12—peripheral nervous system neoplasm	0.000208	0.016	CbGpPWpGaD
Tapentadol—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000205	0.000395	CcSEcCtD
Tapentadol—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000204	0.000393	CcSEcCtD
Tapentadol—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000199	0.000383	CcSEcCtD
Tapentadol—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000198	0.000381	CcSEcCtD
Tapentadol—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000196	0.000378	CcSEcCtD
Tapentadol—OPRK1—Mecp2 and Associated Rett Syndrome—BDNF—peripheral nervous system neoplasm	0.000196	0.0152	CbGpPWpGaD
Tapentadol—OPRM1—Opioid Signalling—PPP3R1—peripheral nervous system neoplasm	0.000195	0.015	CbGpPWpGaD
Tapentadol—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000191	0.000367	CcSEcCtD
Tapentadol—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.00019	0.000365	CcSEcCtD
Tapentadol—OPRD1—Peptide ligand-binding receptors—NTS—peripheral nervous system neoplasm	0.00019	0.0147	CbGpPWpGaD
Tapentadol—Rash—Epirubicin—peripheral nervous system neoplasm	0.000189	0.000364	CcSEcCtD
Tapentadol—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000189	0.000363	CcSEcCtD
Tapentadol—Headache—Epirubicin—peripheral nervous system neoplasm	0.000188	0.000361	CcSEcCtD
Tapentadol—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000184	0.000353	CcSEcCtD
Tapentadol—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000178	0.000343	CcSEcCtD
Tapentadol—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000176	0.000339	CcSEcCtD
Tapentadol—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000175	0.000337	CcSEcCtD
Tapentadol—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000175	0.000336	CcSEcCtD
Tapentadol—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000174	0.000334	CcSEcCtD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	0.000172	0.0133	CbGpPWpGaD
Tapentadol—OPRK1—Peptide ligand-binding receptors—NTS—peripheral nervous system neoplasm	0.000166	0.0129	CbGpPWpGaD
Tapentadol—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000165	0.000317	CcSEcCtD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	0.000157	0.0122	CbGpPWpGaD
Tapentadol—OPRM1—Peptide ligand-binding receptors—NTS—peripheral nervous system neoplasm	0.000141	0.0109	CbGpPWpGaD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.000128	0.0099	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000127	0.00983	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000112	0.00862	CbGpPWpGaD
Tapentadol—CYP2C19—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000108	0.00837	CbGpPWpGaD
Tapentadol—UGT1A9—PPAR Alpha Pathway—MYC—peripheral nervous system neoplasm	0.000108	0.00834	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	0.000107	0.00828	CbGpPWpGaD
Tapentadol—UGT2B7—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000107	0.00824	CbGpPWpGaD
Tapentadol—SLC6A4—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000105	0.00812	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000102	0.00787	CbGpPWpGaD
Tapentadol—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	9.89e-05	0.00763	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	9.82e-05	0.00759	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—NTS—peripheral nervous system neoplasm	9.7e-05	0.00749	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	9.44e-05	0.00729	CbGpPWpGaD
Tapentadol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	9.42e-05	0.00727	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—CD55—peripheral nervous system neoplasm	9.3e-05	0.00718	CbGpPWpGaD
Tapentadol—SLC6A2—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	9.04e-05	0.00698	CbGpPWpGaD
Tapentadol—UGT1A9—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	8.68e-05	0.0067	CbGpPWpGaD
Tapentadol—OPRD1—Peptide ligand-binding receptors—KNG1—peripheral nervous system neoplasm	8.53e-05	0.00659	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—NTS—peripheral nervous system neoplasm	8.5e-05	0.00657	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	8.28e-05	0.00639	CbGpPWpGaD
Tapentadol—UGT2B7—NRF2 pathway—HGF—peripheral nervous system neoplasm	8.18e-05	0.00632	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—CD55—peripheral nervous system neoplasm	8.15e-05	0.0063	CbGpPWpGaD
Tapentadol—SLC6A4—NRF2 pathway—HGF—peripheral nervous system neoplasm	8.05e-05	0.00622	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—TH—peripheral nervous system neoplasm	8.02e-05	0.00619	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	8e-05	0.00618	CbGpPWpGaD
Tapentadol—OPRK1—Peptide ligand-binding receptors—KNG1—peripheral nervous system neoplasm	7.48e-05	0.00578	CbGpPWpGaD
Tapentadol—OPRD1—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	7.2e-05	0.00556	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—NTS—peripheral nervous system neoplasm	7.19e-05	0.00555	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	7.14e-05	0.00551	CbGpPWpGaD
Tapentadol—OPRM1—TCR Signaling Pathway—PTPN11—peripheral nervous system neoplasm	6.98e-05	0.00539	CbGpPWpGaD
Tapentadol—SLC6A2—NRF2 pathway—HGF—peripheral nervous system neoplasm	6.93e-05	0.00535	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—CD55—peripheral nervous system neoplasm	6.89e-05	0.00532	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PPIP5K2—peripheral nervous system neoplasm	6.71e-05	0.00518	CbGpPWpGaD
Tapentadol—UGT1A9—NRF2 pathway—HGF—peripheral nervous system neoplasm	6.65e-05	0.00513	CbGpPWpGaD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	6.41e-05	0.00495	CbGpPWpGaD
Tapentadol—OPRM1—Peptide ligand-binding receptors—KNG1—peripheral nervous system neoplasm	6.32e-05	0.00488	CbGpPWpGaD
Tapentadol—OPRK1—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	6.31e-05	0.00487	CbGpPWpGaD
Tapentadol—OPRD1—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	6.29e-05	0.00486	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	5.72e-05	0.00442	CbGpPWpGaD
Tapentadol—SLC6A2—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	5.7e-05	0.0044	CbGpPWpGaD
Tapentadol—OPRK1—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	5.52e-05	0.00426	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	5.48e-05	0.00423	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	5.47e-05	0.00422	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PPIP5K2—peripheral nervous system neoplasm	5.46e-05	0.00421	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	5.39e-05	0.00416	CbGpPWpGaD
Tapentadol—OPRM1—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	5.33e-05	0.00412	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	5.02e-05	0.00387	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—NTS—peripheral nervous system neoplasm	4.98e-05	0.00384	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	4.81e-05	0.00371	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—CD55—peripheral nervous system neoplasm	4.77e-05	0.00368	CbGpPWpGaD
Tapentadol—OPRM1—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	4.66e-05	0.0036	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.54e-05	0.0035	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—NTS—peripheral nervous system neoplasm	4.36e-05	0.00337	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	4.36e-05	0.00336	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	4.34e-05	0.00335	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	4.26e-05	0.00329	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	4.24e-05	0.00327	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—CD55—peripheral nervous system neoplasm	4.18e-05	0.00323	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	4.15e-05	0.00321	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	4.06e-05	0.00314	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	4e-05	0.00309	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	3.89e-05	0.003	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	3.82e-05	0.00295	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	3.81e-05	0.00294	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—VIP—peripheral nervous system neoplasm	3.77e-05	0.00291	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—NTS—peripheral nervous system neoplasm	3.69e-05	0.00285	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—HSD17B12—peripheral nervous system neoplasm	3.69e-05	0.00285	CbGpPWpGaD
Tapentadol—OPRM1—IL4-mediated signaling events—AKT1—peripheral nervous system neoplasm	3.66e-05	0.00282	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	3.64e-05	0.00281	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	3.55e-05	0.00274	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CD55—peripheral nervous system neoplasm	3.54e-05	0.00273	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	3.48e-05	0.00269	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	3.34e-05	0.00258	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—VIP—peripheral nervous system neoplasm	3.31e-05	0.00255	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—GNS—peripheral nervous system neoplasm	3.28e-05	0.00253	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	3.23e-05	0.00249	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—NME1—peripheral nervous system neoplasm	3.14e-05	0.00243	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	3.08e-05	0.00238	CbGpPWpGaD
Tapentadol—OPRM1—TCR Signaling Pathway—HRAS—peripheral nervous system neoplasm	3.07e-05	0.00237	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	3.06e-05	0.00237	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	3.05e-05	0.00236	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—COX2—peripheral nervous system neoplasm	3.03e-05	0.00234	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.94e-05	0.00227	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	2.89e-05	0.00223	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	2.82e-05	0.00218	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.82e-05	0.00218	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—VIP—peripheral nervous system neoplasm	2.8e-05	0.00216	CbGpPWpGaD
Tapentadol—OPRM1—TCR Signaling Pathway—AKT1—peripheral nervous system neoplasm	2.71e-05	0.00209	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GNS—peripheral nervous system neoplasm	2.66e-05	0.00206	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	2.58e-05	0.00199	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.58e-05	0.00199	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.56e-05	0.00198	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—NME1—peripheral nervous system neoplasm	2.55e-05	0.00197	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.47e-05	0.00191	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.46e-05	0.0019	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—COX2—peripheral nervous system neoplasm	2.46e-05	0.0019	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.36e-05	0.00182	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.34e-05	0.00181	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	2.33e-05	0.0018	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	2.29e-05	0.00176	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	2.24e-05	0.00173	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—VIP—peripheral nervous system neoplasm	2.23e-05	0.00172	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.18e-05	0.00168	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.16e-05	0.00167	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	2.15e-05	0.00166	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	2.09e-05	0.00162	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.09e-05	0.00161	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	2.06e-05	0.00159	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—ENO2—peripheral nervous system neoplasm	1.99e-05	0.00153	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.96e-05	0.00151	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.96e-05	0.00151	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.95e-05	0.00151	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.89e-05	0.00146	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	1.82e-05	0.00141	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.8e-05	0.00139	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.73e-05	0.00134	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.71e-05	0.00132	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—BCHE—peripheral nervous system neoplasm	1.68e-05	0.0013	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.66e-05	0.00128	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.65e-05	0.00128	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ENO2—peripheral nervous system neoplasm	1.61e-05	0.00125	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.6e-05	0.00124	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.6e-05	0.00123	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.59e-05	0.00123	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.58e-05	0.00122	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—TH—peripheral nervous system neoplasm	1.58e-05	0.00122	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.54e-05	0.00119	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.52e-05	0.00118	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.45e-05	0.00112	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.44e-05	0.00111	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—BCHE—peripheral nervous system neoplasm	1.36e-05	0.00105	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.36e-05	0.00105	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.35e-05	0.00105	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.32e-05	0.00102	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.31e-05	0.00101	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.3e-05	0.001	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—GNAS—peripheral nervous system neoplasm	1.29e-05	0.000995	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—TH—peripheral nervous system neoplasm	1.28e-05	0.00099	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—ABCB1—peripheral nervous system neoplasm	1.26e-05	0.000976	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.26e-05	0.000972	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GNS—peripheral nervous system neoplasm	1.25e-05	0.000967	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NME1—peripheral nervous system neoplasm	1.2e-05	0.000927	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.19e-05	0.00092	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.16e-05	0.000894	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—COX2—peripheral nervous system neoplasm	1.16e-05	0.000892	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.16e-05	0.000892	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GNS—peripheral nervous system neoplasm	1.15e-05	0.000889	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.14e-05	0.000884	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GNS—peripheral nervous system neoplasm	1.14e-05	0.000882	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NME1—peripheral nervous system neoplasm	1.1e-05	0.000853	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.1e-05	0.000852	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NME1—peripheral nervous system neoplasm	1.09e-05	0.000845	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—COX2—peripheral nervous system neoplasm	1.06e-05	0.000821	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—COX2—peripheral nervous system neoplasm	1.05e-05	0.000814	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GNAS—peripheral nervous system neoplasm	1.05e-05	0.000808	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ABCB1—peripheral nervous system neoplasm	1.03e-05	0.000793	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.01e-05	0.000782	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.01e-05	0.000778	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	9.79e-06	0.000756	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	9.33e-06	0.00072	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	8.56e-06	0.000661	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	8.17e-06	0.000631	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	8.03e-06	0.00062	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ENO2—peripheral nervous system neoplasm	7.59e-06	0.000586	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	7.16e-06	0.000553	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.04e-06	0.000544	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	6.98e-06	0.000539	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	6.92e-06	0.000534	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—BCHE—peripheral nervous system neoplasm	6.41e-06	0.000495	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.34e-06	0.00049	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.12e-06	0.000472	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.06e-06	0.000468	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—TH—peripheral nervous system neoplasm	6.03e-06	0.000465	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	5.98e-06	0.000462	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.95e-06	0.000459	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	5.9e-06	0.000455	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	5.85e-06	0.000451	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	5.81e-06	0.000449	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.76e-06	0.000445	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.63e-06	0.000434	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.58e-06	0.000431	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.56e-06	0.00043	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	5.54e-06	0.000428	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	5.5e-06	0.000424	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	5.28e-06	0.000408	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	5.24e-06	0.000405	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	5.1e-06	0.000394	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.05e-06	0.00039	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GNAS—peripheral nervous system neoplasm	4.92e-06	0.00038	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ABCB1—peripheral nervous system neoplasm	4.83e-06	0.000373	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.83e-06	0.000373	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.7e-06	0.000363	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.63e-06	0.000357	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	4.53e-06	0.000349	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.5e-06	0.000347	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	4.49e-06	0.000346	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	4.44e-06	0.000343	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.43e-06	0.000342	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	4.4e-06	0.00034	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.31e-06	0.000333	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.27e-06	0.00033	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.23e-06	0.000327	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.94e-06	0.000304	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	3.91e-06	0.000302	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.69e-06	0.000285	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.58e-06	0.000276	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.53e-06	0.000273	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—AKT1—peripheral nervous system neoplasm	3.48e-06	0.000269	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.33e-06	0.000257	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.24e-06	0.00025	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.12e-06	0.000241	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.1e-06	0.000239	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—AKT1—peripheral nervous system neoplasm	2.83e-06	0.000218	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.74e-06	0.000211	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.73e-06	0.000211	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.62e-06	0.000202	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.31e-06	0.000178	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—AKT1—peripheral nervous system neoplasm	1.33e-06	0.000103	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	1.22e-06	9.43e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	1.21e-06	9.35e-05	CbGpPWpGaD
